Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smith & Nephew Seeks To Buy India's Adler Mediequip For $300 Million

This article was originally published in PharmAsia News

Executive Summary

India's Adler Mediequip Private, maker of medical devices for use in treating traumas, is the target of a $300 million buyout effort by the U.K.'s Smith & Nephew, which said it intends to acquire the company and its brands.

India's Adler Mediequip Private, maker of medical devices for use in treating traumas, is the target of a $300 million buyout effort by the U.K.'s Smith & Nephew, which said it intends to acquire the company and its brands. The U.K. giant said it would attempt to buy Adler shares to expand its businesses in wound-care and minimally invasive-surgery devices. The Smith & Nephew move followed closely on the heels of its $70 million acquisition of Pro Cirurgia Especializada distributor in Brazil. (Click here for more)

"Smith & Nephew Buys India Trauma Business to Return To Growth" - Bloomberg (U.S.) (5/2/2013)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC084451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel